相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RAGE Controls Activation and Anti-Inflammatory Signalling of Protein C
Natascha Braach et al.
PLOS ONE (2014)
Tonic regulation of vascular permeability
F. -R. E. Curry et al.
ACTA PHYSIOLOGICA (2013)
Recombinant Human Activated Protein C as a Therapy for Severe Sepsis: Lessons Learned?
Steven M. Opal et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)
Liesbeth M. Kager et al.
CRITICAL CARE MEDICINE (2013)
Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis)
L. M. Kager et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Thrombosis as an intravascular effector of innate immunity
Bernd Engelmann et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Drotrecogin Alfa (Activated) in Adults with Septic Shock
V. Marco Ranieri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study
Marcel Schouten et al.
CRITICAL CARE (2012)
The effect of inflammation on coagulation and vice versa
Tom van der Poll et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2011)
Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis
Andrew D. Shaw et al.
JOURNAL OF CRITICAL CARE (2011)
Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia
Marcel Schouten et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Inflammation and coagulation
Marcel Levi et al.
CRITICAL CARE MEDICINE (2010)
Therapeutic Recombinant Murine Activated Protein C Attenuates Pulmonary Coagulopathy and Improves Survival in Murine Pneumococcal Pneumonia
Marcel Schouten et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Recombinant human activated protein C inhibits integrin-mediated neutrophil migration
Gwendolyn F. Elphick et al.
BLOOD (2009)
Coagulation and innate immune responses: can we view them separately?
Mieke Delvaeye et al.
BLOOD (2009)
Pathogenesis, treatment, and prevention of pneumococcal pneumonia
Tom van der Poll et al.
LANCET (2009)
Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions
H. F. Galley et al.
BRITISH JOURNAL OF ANAESTHESIA (2008)
Mechanisms of disease: Acute lower respiratory tract infection
Joseph P. Mizgerd
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis
Berend Isermann et al.
NATURE MEDICINE (2007)
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment
S. H. Slofstra et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock
Linda A. Kirschenbaum et al.
CRITICAL CARE MEDICINE (2006)
Inflammation and the activated protein C anticoagulant pathway
Charles T. Esmon
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study
PF Laterre et al.
CRITICAL CARE MEDICINE (2005)
Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation
C Feistritzer et al.
BLOOD (2005)
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis
JA Nick et al.
BLOOD (2004)
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)
SM Opal et al.
CLINICAL INFECTIOUS DISEASES (2003)
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
EW Ely et al.
CRITICAL CARE MEDICINE (2003)
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
WL Macias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
CJ Fisher et al.
CRITICAL CARE MEDICINE (2000)
分享论文
